MeSH tree: C15.604.515.560.080
Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center have identified a cocktail of three different drugs that can be used to generate more robust immune system CAR-Ts ...
Jan 13, 2025
0
8
In blood cancers such as chronic lymphocytic leukemia, B cells of the immune system multiply uncontrollably. One form of therapy involves labeling the CD20 protein on the surface of the B cells with customized antibodies. ...
Jan 10, 2025
0
27
A novel, fixed-duration drug combination—consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug—shows deep and durable responses ...
Dec 9, 2024
0
0
Harvard geneticist Gary Ruvkun vividly remembers the late-night phone call with his longtime friend and now 2024 Nobel Prize in Medicine co-laureate Victor Ambros, when they made their groundbreaking discovery of genetic ...
Oct 8, 2024
0
28
RNA-sequencing has become a cornerstone in the study of gene expression, offering insights beyond mere mRNA transcript abundances. One area of increasing interest is alternative splicing, a process that allows a single gene ...
Sep 13, 2024
0
20
About 8 to 10 million Americans over age 40 have an overabundance of cloned white blood cells, or lymphocytes, that hamper their immune systems. Although many who have this condition—called monoclonal B-cell lymphocytosis ...
Sep 6, 2024
0
17
For many doctors and researchers, immunotherapy that uses someone's own immune system to target and attack cancer cells is the next and best frontier of cancer treatment. Chimeric antigen receptor T-cell therapy, or CAR-T ...
Sep 3, 2024
0
1
A new editorial titled "Strategies to disrupt NKG2A:HLA-E interactions for improved anti-cancer immunity" has been published in Oncotarget.
Aug 21, 2024
0
0
First-line ibrutinib is associated with better outcomes than chemoimmunotherapy among patients with chronic lymphocytic leukemia (CLL), according to a study published online May 13 in Clinical Lymphoma, Myeloma & Leukemia.
Jun 21, 2024
0
2
Patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHLs) who received frequent tests for immunoglobulin G (IgG) were less likely to experience severe infections compared with those who didn't, according ...
Jun 21, 2024
0
0
